0WA2 Stock Chart & Stats
€2.52
€0.05(1.95%)
At close: 4:00 PM EDT
€2.52
€0.05(1.95%)
Day’s Range― - ―
52-Week Range€2.07 - €4.84
Previous CloseN/A
Volume283.00
Average Volume (3M)7.30K
Market Cap
€181.39M
Enterprise Value€205.35
Total Cash (Recent Filing)€185.47M
Total Debt (Recent Filing)€82.33M
Price to Earnings (P/E)―
Beta0.32
Next Earnings
Nov 09, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding72,325,455
10 Day Avg. Volume5,208
30 Day Avg. Volume7,305
Financial Highlights & Ratios
PEG Ratio-0.10
Price to Book (P/B)6.52
Price to Sales (P/S)6.52
P/FCF Ratio-11.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.74
Revenue Forecast (FY)€52.22M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained high gross margins indicate the underlying cell‑therapy and technology services have attractive incremental economics; this supports scalability and partner economics, meaning once R&D and fixed costs are absorbed, revenue growth can translate more efficiently to operating leverage over time.
Platform-oriented Business ModelA technology/partnership-driven model (collaborations, licensing, manufacturing services) diversifies funding sources and de-risks single-product reliance. Long-term, this enables non-dilutive milestone and service revenue streams and strategic alliances that can accelerate development and commercialization paths.
Improving Revenue ScaleRevenue has moved materially higher from prior troughs and shows positive multi-year growth, reflecting expanding partner activities and service income. A growing top line provides a firmer base to leverage high gross margins and, if sustained, can support eventual improvements in operating leverage and cash generation.
Bears Say
Persistent Cash BurnOngoing negative operating and free cash flow indicate the company relies on external financing to fund R&D and operations. This structural cash burn constrains runway, increases dilution/refinancing risk, and limits discretionary investment in programs until cash generation or partner funding reliably improves.
Rising Leverage And Eroding EquityElevated and increasing leverage coupled with a shrinking equity base reduces financial flexibility and heightens refinancing risk. This structural weakening may force higher-cost capital, constrain strategic options, and limit ability to fund development internally without dilutive or restrictive financing terms.
Deep Operating LossesSevere and persistent negative margins mean current operations do not generate profits even with strong gross margins. Until operating costs are reduced or revenues scale substantially, losses will pressure returns, raise capital needs, and hinder the company's ability to reinvest in programs without external support.
Cellectis SA News
0WA2 FAQ
What was Cellectis SA’s price range in the past 12 months?
Cellectis SA lowest share price was €2.07 and its highest was €4.84 in the past 12 months.
What is Cellectis SA’s market cap?
Cellectis SA’s market cap is €181.39M.
When is Cellectis SA’s upcoming earnings report date?
Cellectis SA’s upcoming earnings report date is Nov 09, 2026 which is in 88 days.
How were Cellectis SA’s earnings last quarter?
Cellectis SA released its earnings results on Aug 06, 2026. The company reported -€0.19 earnings per share for the quarter, beating the consensus estimate of -€0.227 by €0.037.
Is Cellectis SA overvalued?
According to Wall Street analysts Cellectis SA’s price is currently Overvalued.
Does Cellectis SA pay dividends?
Cellectis SA does not currently pay dividends.
What is Cellectis SA’s EPS estimate?
Cellectis SA’s EPS estimate is -0.18.
How many shares outstanding does Cellectis SA have?
Cellectis SA has 72,325,455 shares outstanding.
What happened to Cellectis SA’s price movement after its last earnings report?
Cellectis SA reported an EPS of -€0.19 in its last earnings report, beating expectations of -€0.227. Following the earnings report the stock price went down -1.703%.
Which hedge fund is a major shareholder of Cellectis SA?
Currently, no hedge funds are holding shares in GB:0WA2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cellectis SA
Cellectis S.A., a clinical-stage biotechnology company founded in 1999 and headquartered in Paris, France, concentrates on immuno-oncology. The firm engineers therapeutic solutions utilizing gene-edited T-cells, which are modified to display chimeric antigen receptors (CARs) for the specific identification and destruction of cancer cells. Its operations are divided into two principal segments: Therapeutics and Plants. The company's pipeline features several allogeneic CAR T-cell product candidates. These include UCART19, aimed at CD19-expressing hematologic malignancies such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A, developed to treat relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316, targeting renal cell carcinoma; UCART123, for acute myeloid leukemia; and UCART22, addressing B-cell acute lymphoblastic leukemia. Additionally, Cellectis is advancing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. Cellectis has forged significant strategic partnerships and alliances with companies including Allogene Therapeutics, Inc., Les Laboratoires Servier, The University of Texas M.D. Anderson Cancer Center, and Iovance Biotherapeutics. It also maintains a strategic research and development collaboration with Cytovia Therapeutics, Inc.
0WA2 Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in advancing pivotal clinical trials and maintaining a strong financial position, with ongoing collaborations and upcoming strategic events. However, ongoing arbitration and a decrease in cash reserves posed challenges.View all GB:0WA2 earnings summariesTechnical Analysis
Innate Pharma SA
―
Nanobiotix
―
Transgene
―
OSE Immunotherapeutics SA
―
MaaT Pharma
―